Lumbosacral Radicular Pain or Sciatica – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Lumbar radiculopathy is one of the most common complaints affecting men and women. Age is a primary risk factor, as it occurs secondary to the degenerative process within the spinal column. Symptoms typically begin in midlife, with men often affected in the 40s while women are involved in the 50s and 60s. Females have a higher risk in specific populations, with physically demanding careers such as service in the military. In the general population, there is a male preponderance. Degenerative spondyloarthropathies are the primary cause of lumbar radiculopathy. Patients commonly present with back pain that is associated with their radiculopathy. By definition, radiculopathy describes pain that radiates down the legs and is often characterized by patients as electric, burning, or sharp.

The prevalence ranges between 3% to 5% of the population age 40 and above, both in men and women. It occurs secondary to the degenerative process within the spinal column. Symptoms typically begin in midlife, with men often affected in the 40s while women are involved in the 50s and 60s.

 

The competitive landscape of Lumbosacral Radicular Pain or Sciatica includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Lumbosacral Radicular Pain or Sciatica across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Lumbosacral Radicular Pain or Sciatica Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Lumbosacral Radicular Pain or Sciatica – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          SP-102 Scilex Pharmaceuticals, Inc.      Phase 3

2          ETX-018810      Eliem Therapeutics (UK) Ltd.     Phase 2

3          CEP-37247       Cephalon          Phase 2

4          SX600  SpineThera Australia PTY LTD   Phase 2